Insider Selling: Vir Biotechnology (NASDAQ:VIR) CAO Sells 1,430 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,430 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $9.53, for a total transaction of $13,627.90. Following the sale, the chief accounting officer directly owned 69,613 shares in the company, valued at $663,411.89. The trade was a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Brent Sabatini also recently made the following trade(s):

• On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total transaction of $13,626.05.
• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.79, for a total transaction of $11,918.70.

Vir Biotechnology Trading Down 6.8%

NASDAQ:VIR traded down $0.68 during trading hours on Thursday, hitting $9.32. 21,297,575 shares of the company were exchanged, compared to its average volume of 3,752,478. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -2.95 and a beta of 1.69. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.94. The company has a fifty day simple moving average of $6.88 and a 200 day simple moving average of $6.02.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The firm’s revenue was up 417.8% compared to the same quarter last year. During the same period last year, the company earned ($0.76) earnings per share. Equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on VIR shares. Morgan Stanley lifted their target price on shares of Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James Financial raised Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective for the company in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a report on Tuesday, December 30th. Finally, Barclays boosted their price target on Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.89.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds have recently added to or reduced their stakes in VIR. ARCH Venture Management LLC acquired a new position in shares of Vir Biotechnology during the second quarter worth approximately $65,100,000. GSK plc bought a new stake in Vir Biotechnology during the 4th quarter valued at $51,562,000. State Street Corp increased its stake in Vir Biotechnology by 18.9% during the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after purchasing an additional 988,262 shares in the last quarter. Orbimed Advisors LLC raised its holdings in Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock worth $11,999,000 after buying an additional 132,466 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Vir Biotechnology by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock valued at $14,041,000 after buying an additional 81,985 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology News Summary

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas collaboration materially derisks VIR‑5500 and adds near‑term cash/validation — the global co‑development/co‑commercialization deal includes significant upfront/near‑term payments and up to large milestone upside, boosting the program’s commercial outlook. Astellas and Vir Biotechnology collaborate on VIR-5500
• Positive Sentiment: Updated Phase 1 data for VIR‑5500 show encouraging safety and activity (notable higher‑dose response rates), supporting the asset value that underpins the Astellas deal. VIR-5500 Phase 1 results
• Positive Sentiment: Quarterly beat and revenue surge: Q4 EPS topped estimates and revenue (~$64.1M) far exceeded consensus, helping justify higher analyst targets and fueling recent upside. Vir Q4 earnings highlights
• Positive Sentiment: Analyst support: Needham and other firms raised targets/ratings after the results and deal news, reinforcing bullish institutional views. Needham raises VIR price target
• Neutral Sentiment: Management will be highly visible to investors in March (TD Cowen, Leerink) — useful for clarification on milestones, commercialization plans and cash use. Investor conference participation
• Neutral Sentiment: Media and valuation pieces are amplifying interest and volume — increased coverage raises visibility but doesn’t change fundamentals alone. Valuation after collaboration & Phase 1 update
• Negative Sentiment: Public offering priced: Vir priced 17,647,058 shares at $8.50 (gross proceeds about $150M). Proceeds bolster the balance sheet but the issuance is dilutive and can pressure the stock near term. Public offering priced
• Negative Sentiment: Clustered insider selling: Multiple insiders (CEO, EVPs, CFO, CAO, a director) reported stock sales across Feb. 23–25 — increases visible supply and can weigh on sentiment despite company progress. Insider selling report
• Negative Sentiment: Ongoing losses: Despite revenue growth and partnership cash, Vir reported a sizable net loss and wide negative margins — long‑term upside depends on execution, milestones and commercial ramp. 2025 financial results

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.